Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»US News

    Novo Nordisk weight loss drugs linked to rare eye condition: study

    By July 7, 2024 US News
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    Novo Nordisk weight loss drugs linked to rare eye condition: study

    A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. 

    George Frey | Reuters

    Novo Nordisk investors appeared unperturbed Thursday by a critical Harvard report that linked weight loss drugs to a rare eye condition.

    Semaglutide, which is present in weight loss drugs including Novo Nordisk’s Ozempic and Wegovy, might be associated with an increased risk of a rare eye disease, according to a study carried out by Harvard Medical School.

    Analysts said the study results were “hardly a game-changer,” however. Shares in the Danish pharmaceutical company’s shares were little changed on Thursday, dipping in early morning trade before rising 0.1% as of 11:17 a.m. London time.

    The Harvard report found that patients with type 2 diabetes or obesity, who are prescribed semaglutide, have an increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) — a condition which can lead to loss of vision in one eye. Patients were more likely to be diagnosed with the eye condition compared to patients who were not prescribed the weight loss drugs, the study found.

    While the research paper does suggest “some correlation” with a rare ocular event, the quality of the evidence is “vey low, the error bars are very wide,” according to Deutsche Bank analyst Emmanuel Papadakis.

    The worst case scenario would likely be a further update to the label warning section of the drugs, which is “hardly a game-changer,” said Papadakis.

    He added that Deutsche Bank generally regards semaglutide medications as “one of the most derisked therapeutic classes in industry history from a safety perspective.”

    A spokesperson from Novo Nordisk said the optic nerve disease NAION is not an “adverse drug reaction for the marketed formulations of semaglutide” as per the approved labels. They added that there are “key methodological limitations” to the study such as the “small number of people” with type 2 diabetes or obesity that were exposed to semaglutide and were included in the trial.

    “Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from use of our medicines very seriously,” the spokesperson said.

    Novo Nordisk showed 'extraordinary growth' but faces competitive weight loss market: Novasecta

    Popularity for the blockbuster drugs has seen Novo Nordisk grow to become the most valuable company in Europe, with a valuation larger than Denmark’s total gross domestic product last year.

    Wegovy has also been shown to have health benefits beyond losing weight and regulating blood sugar. The Food and Drug Administration in March approved it for use in reducing the risk of heart disease.

    The drugs, however, have faced scrutiny after some patients reported experiencing stomach paralysis and suicidal ideation while taking them. A study carried out by researchers at the University of British Columbia noted an increased risk of bowel obstruction, a disorder where food is blocked from passing through the small or large intestine, and pancreatitis, or pancreas inflammation.

    The labels for the drugs already include warnings about pancreatitis and certain types of bowel obstruction. A change in vision is also listed as a potential side effect for both Ozempic and Wegovy.

    The U.S. study, which was published on Wednesday, analyzed data from 16,827 patients from December 2017 through to November last year. The researchers noted that further study is required to assess whether semaglutide causes the eye condition.

    — CNBC’s Jenni Reid contributed to this report.

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Wash. officials condemn ICE after 2 arrested boarding flight at Seattle airport

    November 22, 2026

    What's behind the uptick in attacks in the Strait of Hormuz?

    November 21, 2026

    Body of missing 19-year-old Marine found: Sheriff's department

    November 21, 2026

    DOJ dropping Alaska midterms Senate certification lawsuit, saying case is 'moot'

    November 20, 2026

    JPMorganChase reports cyberattack on third-party service providers

    November 19, 2026

    Musk regrets nearly $500 million midterm elections spending, says hes not MAGA

    November 19, 2026
    Popular Posts

    Guarding Stars Writers Break Down The Bodyguard Title Change

    Holiday airfares hit highest levels in a decade as jet fuel prices surge

    Aaron Pierre on his future in the DCU: Im very at peace

    Rosalía Calls Taylor Swift a Master Songwriter, Reveals Her Favorite Swift Track

    Experts warn: Nearly everyone in AI is susceptible to a honey-trap scheme right now | TechCrunch

    Race realism isnt realistic—and it isnt good science

    Categories
    • Books (2,462)
    • Business (3,452)
    • Events (34)
    • Film (1,067)
    • LifeStyle (2,926)
    • Music (2,801)
    • Politics (2,356)
    • Science (1,957)
    • Technology (1,822)
    • Television (3,633)
    • US News (3,298)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • When Saving the Ocean Starts on Land: The Human Story Behind a Conservation BreakthroughWhen Saving the Ocean Starts on Land: The Human Story Behind a Conservation Breakthrough
    • Luke Kleintank Exiting in Season 3Luke Kleintank Exiting in Season 3
    • Comedy or Tragedy? Autonomous Taxis By Howard BloomComedy or Tragedy? Autonomous Taxis By Howard Bloom
    • Carey Mulligan Told Us the Most Slept-On Mumford & Sons SongCarey Mulligan Told Us the Most Slept-On Mumford & Sons Song
    • We’re Thinking About Space All Wrong Humanity Must Stop Visiting Space, and Start Living There  By Erinn van Wynsberghe  Founder, VanWyn With Howard Bloom, Founder & Chair, Space Development Steering CommitteeWe’re Thinking About Space All Wrong Humanity Must Stop Visiting Space, and Start Living There By Erinn van Wynsberghe Founder, VanWyn With Howard Bloom, Founder & Chair, Space Development Steering Committee
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.